Hepatotoxicity of Antituberculosis Therapy (HAT) Study

NCT04159441 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 5000

Last updated 2019-11-12

No results posted yet for this study

Summary

Drug-induced liver injury (DILI) is a common side effect in antituberculosis therapy, which interuputs the treatment of TB and leads to a higher proportion of Multidrug-Resistence TB(MDR-TB).The study primalily aims to observe the proportion of DILI in antituberculosis therapy. Furthermore, the secondary objective is to study the proportion of liver injury of based liver disase,liver failure and adjustment of chemotherapy in the obersevational study.

Conditions

  • Chemical and Drug Induced Liver Injury

Interventions

OTHER

None intervetion

None intervetion

Sponsors & Collaborators

  • Huashan Hospital

    lead OTHER

Principal Investigators

  • Wenhong Zhang · Huashan Hospital

  • Yongguo LI · First Affiliated Hospital of Harbin Medical University

  • Dapeng Bai · Haihe Hospital in Tianjin

  • Meiying Wu · The Fifth Hospital in Suzhou

  • Huaicheng Wang · Third People's Hospital in Changzhou

  • Qinfang Ou · Fifth Hospital in Wuxi

  • Yonglan Pu · First People's Hospital in Taicang

  • Fan Xia · The 905th Hospital of the PLA Navy

  • Yuanyuan Chen · Red Cross Hospital, Hangzhou, China

  • Zumo Zhou · People's Hospital in Zhuji

  • Xiaohong Chen · Fuzhou Pulmonary Hospital in Fujian

  • Guofang Deng · The Third People's Hospital in Shenzhen

  • Shiwu Ma · People's Liberation Army Joint Service Support Unit 920 Hospital (formerly Kunming General Hospital of Chengdu Military Region)

  • Youfang Gao · People's Hospital in Haozhou

  • Yongfang Jiang · Central South University Xiangya Second Hospital

  • Hongying Yu · Huaihua First People Hospital in Hunan

  • Bo Chen · Longtan Hospital in Guangxi

  • Weiqiang Zheng · Guangdong Medical University Affiliated Hospital

  • Liyuan Zhang · The Second Affiliated Hospital of Hainan Medical College

  • Guanghui Xu · Tuberculosis Control Center in Jiangmen

  • Anjie Zhang · Yubei Second People's Hospital

  • Hancheng Liang · The Sixth People's Hospital in Dongguan

  • Yuqing Wu · Chest Hospital in Jiangxi

  • Xilin Zhang · The Forth People's Hospital in Foshan

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-05
Primary Completion
2020-12-05
Completion
2021-06-05

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04159441 on ClinicalTrials.gov